<XML><RECORDS><RECORD><REFERENCE_TYPE>0</REFERENCE_TYPE><REFNUM>9237</REFNUM><AUTHORS><AUTHOR>Kearney,N.</AUTHOR><AUTHOR>McCann,L.</AUTHOR><AUTHOR>Norrie,J.</AUTHOR><AUTHOR>Taylor,L.</AUTHOR><AUTHOR>Gray,P.</AUTHOR><AUTHOR>McGee-Lennon,M.R.</AUTHOR><AUTHOR>Sage,M.</AUTHOR><AUTHOR>Miller,M.</AUTHOR><AUTHOR>Maguire,R.</AUTHOR></AUTHORS><YEAR>2009</YEAR><TITLE>Evaluation of a mobile phone-based, advanced symptom management system (ASyMS©) in the management of chemotherapy-related toxicity</TITLE><PLACE_PUBLISHED>Supportive Care in Cancer</PLACE_PUBLISHED><PUBLISHER>Springer</PUBLISHER><PAGES>437-444</PAGES><ISBN>0941-4355</ISBN><LABEL>Kearney:2009:9237</LABEL><KEYWORDS><KEYWORD>Chemotherapy - Symptoms - Technology - Assessment</KEYWORD></KEYWORDS<ABSTRACT>Objectives To evaluate the impact of a mobile phone-based, remote monitoring, advanced symptom management system (ASyMS©) on the incidence, severity and distress of six chemotherapy-related symptoms (nausea, vomiting, fatigue, mucositis, hand–foot syndrome and diarrhoea) in patients with lung, breast or colorectal cancer. Design A two group (intervention and control) by five time points (baseline, pre-cycle 2, pre-cycle 3, pre-cycle 4 and pre-cycle 5) randomised controlled trial. Setting Seven clinical sites in the UK; five specialist cancer centres and two local district hospitals. Participants One hundred and twelve people with breast, lung or colorectal cancer receiving outpatient chemotherapy. Interventions A mobile phone-based, remote monitoring, advanced symptom management system (ASyMS©). Main outcome measures Chemotherapy-related morbidity of six common chemotherapy-related symptoms (nausea, vomiting, fatigue, mucositis, hand–foot syndrome and diarrhoea). Results There were significantly higher reports of fatigue in the control group compared to the intervention group (odds ratio?=?2.29, 95%CI?=?1.04 to 5.05, P?=?0.040) and reports of hand–foot syndrome were on average lower in the control group (odds ratio control/intervention?=?0.39, 95%CI?=?0.17 to 0.92, P?=?0.031). Conclusion The study demonstrates that ASyMS© can support the management of symptoms in patients with lung, breast and colorectal cancer receiving chemotherapy.</ABSTRACT><URL>http://www.springerlink.com/content/l80147067541h88r/fulltext.pdf</URL></RECORD></RECORDS></XML>